Ovarian cancer treatment typically combines surgery to remove as much cancer as possible with chemotherapy to kill remaining cancer cells. Depending on the stage, genetic profile, and how the cancer responds to initial treatment, targeted therapies and maintenance drugs may also play a significant role. The specific plan varies from person to person, but the overall framework follows a well-established path.
Surgery: The First Major Step
For most people diagnosed with ovarian cancer, treatment begins with surgery. The primary goal is called “debulking” or cytoreductive surgery, which means removing all visible cancer from the abdomen. A cancer is considered optimally debulked when no remaining tumors are larger than 1 centimeter, though surgeons aim to leave no visible disease at all. The more completely the cancer is removed, the better chemotherapy works afterward.
What gets removed depends on how far the cancer has spread. At minimum, the surgeon typically removes both ovaries, the fallopian tubes, and the uterus. The omentum, a fatty tissue layer that drapes over the abdominal organs and is a common site for ovarian cancer spread, is also removed. In more advanced cases, portions of the colon or small intestine may need to come out as well. Lymph nodes in the pelvis and abdomen are sampled or removed for staging purposes.
Some patients receive chemotherapy before surgery (called neoadjuvant chemotherapy) to shrink tumors first, making the operation more effective. This approach is common when the cancer is too widespread for surgery to be the starting point. After a few cycles of chemotherapy, the surgeon reassesses and operates when debulking has the best chance of success.
Chemotherapy After Surgery
The standard first-line chemotherapy for ovarian cancer is a combination of two drugs: a platinum-based agent and a second drug that disrupts cancer cell division. These are given intravenously, typically every three weeks, for about six cycles. Each cycle lasts 21 days, so the full course runs roughly four to five months.
Side effects during this period commonly include fatigue, nausea, hair loss, and lowered blood counts that increase infection risk. Most of these side effects are temporary and improve after treatment ends, though some, like numbness or tingling in the hands and feet, can linger for months. Your oncology team monitors blood work before each cycle to make sure your body can handle the next round.
For some patients, chemotherapy can also be delivered directly into the abdominal cavity (called intraperitoneal chemotherapy), which puts higher concentrations of the drug right where the cancer tends to spread. This route has shown benefits in certain cases but comes with more intense side effects, so it’s not appropriate for everyone.
Genetic Testing Shapes Your Treatment
One of the most important steps early in treatment is genetic testing. Current guidelines recommend that everyone diagnosed with epithelial ovarian cancer be tested for mutations in the BRCA1 and BRCA2 genes. If those results come back negative, a broader test for something called homologous recombination deficiency (HRD) is recommended. These tests look at whether your cancer cells have trouble repairing their own DNA, a weakness that specific drugs can exploit.
About 15 to 20 percent of ovarian cancers carry a BRCA mutation, and a larger proportion have HRD. Knowing your status directly determines which maintenance therapies you’re eligible for after chemotherapy, so this testing isn’t optional. It’s a core part of modern treatment planning.
Maintenance Therapy to Delay Recurrence
After surgery and chemotherapy, many patients don’t simply stop treatment. If the cancer responded well to platinum-based chemotherapy (meaning it shrank significantly or disappeared on imaging), maintenance therapy can extend the time before cancer comes back.
PARP Inhibitors
PARP inhibitors are oral medications that block a DNA repair pathway cancer cells rely on. When cancer cells already have faulty DNA repair (as in BRCA-mutated or HRD-positive tumors), adding a PARP inhibitor essentially traps them with no way to fix damage, causing them to die. Women with BRCA-associated ovarian cancer are typically offered maintenance with a PARP inhibitor for two to three years. Those with high-grade serous or endometrioid ovarian cancer who responded to platinum-based chemotherapy may also be candidates, even without a BRCA mutation.
These drugs are taken as pills at home, which makes them more convenient than IV chemotherapy. Common side effects include fatigue, nausea, and low blood counts, which require regular monitoring through blood tests.
Bevacizumab
Bevacizumab works differently. It targets blood vessel growth, cutting off the blood supply that tumors need to grow. It’s given intravenously alongside chemotherapy and then continued as maintenance. Studies show it improves the time before cancer progresses, with a particularly strong benefit when cancer has already recurred. In some cases, bevacizumab and a PARP inhibitor are used together for maintenance, especially in patients whose tumors test positive for HRD.
What Happens When Cancer Comes Back
Ovarian cancer recurs in the majority of advanced-stage cases, so understanding recurrence treatment is important. How the recurrence is treated depends heavily on timing. If the cancer returns six months or more after the last platinum-based chemotherapy was completed, it’s considered platinum-sensitive. This is meaningful because these cancers are likely to respond to platinum-based treatment again, and retreatment with platinum combinations (paired with a second drug) typically produces strong response rates and longer remissions.
If the cancer returns within six months of finishing platinum treatment, it’s classified as platinum-resistant. These cancers are less likely to respond to the same approach, so different drug options are used. One newer option for platinum-resistant disease is mirvetuximab soravtansine, a targeted therapy that delivers a cell-killing drug directly to cancer cells that express a specific surface protein called folate receptor alpha. In clinical trials, about 83 percent of patients with platinum-resistant cancer saw their tumors shrink in response to this drug combined with an immune checkpoint inhibitor, with a 31 percent objective response rate.
If cancer returns but only shows up as a rising blood marker (CA-125) without visible tumors on imaging and you have no symptoms, immediate chemotherapy isn’t always necessary. Observation or hormonal therapies like tamoxifen or aromatase inhibitors can be reasonable approaches in that situation.
HIPEC: Heated Chemotherapy During Surgery
For cancers that have spread to the lining of the abdominal cavity, a procedure called HIPEC (hyperthermic intraperitoneal chemotherapy) is sometimes an option. After the surgeon removes all visible tumors, heated chemotherapy is pumped directly into the abdomen through catheters for one to two hours. The heat itself helps the drugs penetrate deeper into tissue and makes cancer cells more vulnerable. Afterward, the solution is drained and the abdomen is rinsed before closing.
HIPEC is a major procedure with a significant recovery period, so not everyone is a candidate. Eligibility depends on where the cancer started, how far it has spread, and whether you’re healthy enough to tolerate an extended surgery. It’s most commonly offered at specialized cancer centers.
Survival Rates by Stage
How well treatment works depends largely on how far the cancer has spread at diagnosis. According to the most recent data from the National Cancer Institute (covering 2016 to 2022), the five-year relative survival rates break down as follows:
- Localized (cancer confined to the ovary): 91.9%
- Regional (spread to nearby lymph nodes or tissues): 70.1%
- Distant (cancer has spread to distant organs): 31.5%
These numbers reflect averages across all patients, including those diagnosed years ago before newer treatments like PARP inhibitors became standard. Outcomes for patients starting treatment today, particularly those with BRCA mutations or HRD-positive tumors who can benefit from targeted maintenance therapy, are expected to be better than these historical figures suggest. Stage at diagnosis remains the single strongest predictor, which is why any persistent, unexplained pelvic or abdominal symptoms deserve prompt evaluation.